Setanaxib
As of the edition of 20 October 2026, Setanaxib is a small molecule: in active development; acts on NOX1 and NOX4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2020
- Kind
- Small molecule
- Registered trials
- 8, 0 stopped early
- Disease areas
- Digestive system; Pregnancy and women's health; Urinary and reproductive; Cancer; Hormones; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 6 | 6 | 0 | 0 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Calliditas Therapeutics | Lead sponsor of trials | 2013 to now |
| Calliditas Therapeutics Suisse | Lead sponsor of trials | 2022 to now |